Compare AIRJW & MRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AIRJW | MRK |
|---|---|---|
| Founded | N/A | 2000 |
| Country | United States | United States |
| Employees | 16 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 268.7B |
| IPO Year | N/A | 1994 |
| Metric | AIRJW | MRK |
|---|---|---|
| Price | $0.99 | $120.42 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 17 |
| Target Price | N/A | ★ $125.59 |
| AVG Volume (30 Days) | 99.4K | ★ 7.2M |
| Earning Date | 03-21-2025 | 04-30-2026 |
| Dividend Yield | N/A | ★ 3.06% |
| EPS Growth | N/A | ★ 8.01 |
| EPS | ★ 4.07 | N/A |
| Revenue | N/A | ★ $65,011,000,000.00 |
| Revenue This Year | N/A | $3.61 |
| Revenue Next Year | N/A | $5.41 |
| P/E Ratio | $0.20 | ★ N/A |
| Revenue Growth | N/A | ★ 1.31 |
| 52 Week Low | $0.46 | $75.40 |
| 52 Week High | $1.87 | $125.14 |
| Indicator | AIRJW | MRK |
|---|---|---|
| Relative Strength Index (RSI) | 66.79 | 61.92 |
| Support Level | $0.54 | $112.49 |
| Resistance Level | $1.02 | $124.57 |
| Average True Range (ATR) | 0.12 | 2.54 |
| MACD | 0.03 | 1.18 |
| Stochastic Oscillator | 71.07 | 78.92 |
AirJoule Technologies Corp is an advance technology company whose purpose is to free the world from its water and energy constraints by delivering groundbreaking sorption technologies. The company platform technology, AirJoule, produces pure distilled water from air and, at commercial scale, will mitigate water scarcity through distributed water generation for businesses and consumers around the world. Its products are especially valuable for industrial users, which generate amounts of waste heat that can be used to power sorption technologies to produce low-cost pure distilled water and dehumidified air, two key inputs for a variety of industrial activities, including data centers and advance manufacturing. The Company operates as a single operating and reportable segment.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographical perspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).